Weekly Highlights in Life Sciences and Healthcare (No.30): Key Developments from July 29 to August 4, 2024

July 29,MindRankSelf-developed new drug MRANK-103 completes preclinical candidate compound nomination and enters the IND-Enabling stage.

July 29,AkesoThe new drug application for Edafang®, a globally pioneering PD-1/VEGF bispecific antibody independently developed as a first-line monotherapy for locally advanced or metastatic non-small cell lung cancer with positive PD-L1 expression, has been accepted by the NMPA.

July 29,GSK ChinaThe clinical trial application for dostarlimab injection to treat adult patients with locally advanced, previously untreated mismatch repair-deficient/high microsatellite instability rectal cancer has received tacit approval from the CDE.

July 30,Innostellar BiotherapeuticsGene Therapy Candidate LX101 for the Treatment of Hereditary Retinal Dystrophy Completes Enrollment of All Phase III Clinical Trial Patients

July 30,AutobioAutoLumo A6000 Series Debuts at the 76th American Association for Clinical Chemistry Annual Meeting and Clinical Laboratory Exposition.

July 30,Arctic VisionThe all-new upgraded version of iTEAR Muqin® Self-tear Secretion Stimulator is now officially available for sale.

July 30,AstraZenecaBTK Inhibitor Calquence Combined with Venetoclax Significantly Improves Progression-Free Survival in Previously Untreated Adult Chronic Lymphocytic Leukemia: Phase III Clinical Trial

July 31,NovamabCompleted nearly 200 million yuan in B2 round financing, led by Qiming Venture Partners.

July 31,BiocytogenEntered into an option and license agreement with IDEAYA for a promising first-in-class B7H3/PTK7 BsADC program.

July 31,Hengrui PharmaThe clinical trial application for HRS-6209 in combination with HRS-1358 or HRS-8080 or an aromatase inhibitor or fulvestrant for the treatment of breast cancer has been approved by the NMPA.

August 1,Yimeng AngkeEntered into a licensing and collaboration agreement with Instil for the PD-L1xVEGF bispecific antibody IMM2510 and the next-generation CTLA-4 antibody IMM27M.

August 2,BeOne MedicinesThree clinical trial applications for BGB-24714 in combination with concurrent chemoradiotherapy for the treatment of lung cancer and in combination with concurrent chemoradiotherapy for the treatment of esophageal cancer have been approved by the CDE.

August 2,Hansoh PharmaAlmonertinib Mesylate Tablets Proposed by CDE for Inclusion in Breakthrough Therapy Designation to Treat Unresectable Locally Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletion or Exon 21 Substitution Mutation Without Disease Progression After Platinum-Based Radical Chemoradiotherapy.

August 2,Mabwell9MW2821 Granted Breakthrough Therapy Designation by CDE for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Prior Platinum Chemotherapy and PD-(L)1 Inhibitor Treatment.

Recently,Shanghai Institute of Materia MedicaZhou Bing and Chen Yi's team discovered an effective and selective G9a degrader for the treatment of pancreatic cancer and published their research findings inJournal of Medicinal Chemistry。

Recently,Boehringer IngelheimAcquired Nerio for a total price of $1.3 billion, obtaining an innovative preclinical project.

Recently,KescendThe clinical trial application for CS060304, a self-developed Class 1 new drug for the treatment of homozygous familial hypercholesterolemia, has received tacit approval from the NMPA.

Recently,Miaoshun BioCertified with the international standards of ISO 9001:2015 Quality Management System, ISO 14001:2015 Environmental Management System, and ISO 45001:2018 Occupational Health and Safety Management System.

Recently,DualityBioThe self-developed DB-1311/BNT324 for the clinical treatment of advanced or metastatic esophageal squamous cell carcinoma has been granted Orphan Drug Designation by the FDA.